Primary PFS and interim OS results from TROPION-Lung01 were presented at the ESMO 2023 Congress ... urothelial, gastric, pancreatic, castration-resistant prostate and esophageal cancer. Safety ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

And most recently at ESMO, we presented data on sarcoma ... In addition to our Phase 2 colorectal data, two other Phase 2 trials, as you mentioned, one in pancreas in a refractory setting, and one in ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ... It involved 187 patients with cachexia associated with lung, pancreatic, or colorectal cancer. After 12 weeks of treatment ...

Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enrich ...

Primary PFS and interim OS results from TROPION-Lung01 were presented at the ESMO 2023 Congress ... urothelial, gastric, pancreatic, castration-resistant prostate and esophageal cancer. Safety ...

The SITC posters will be available on ImCheck's corporate website after the poster sessions have been opened.

Q3 2024 Earnings Call Transcript October 30, 2024 Summit Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $-0.07. Operator: Good morning. And welcome to ...